Literature DB >> 1576572

Overcoming problems with polypharmacy and drug misuse in the elderly.

S C Montamat1, B Cusack.   

Abstract

Polypharmacy, the inappropriate use of multiple drug regimens, has a significant impact on the health of elderly individuals. Drug use increases with age, but suitability of therapy is sometimes difficult to define. In ambulatory and hospital care, there is some documentation of poor prescribing practices by physicians and drug misuse by patients. Sound data suggest that polypharmacy and drug misuse are highly prevalent in long-term care facilities. Psychotherapeutic agents are the most commonly misused drugs by physicians in this setting. Polypharmacy is associated with factors such as the number and severity of illnesses, hospitalization, number of physicians seen, number of pharmacies used, and possibly increased patient age. Methods to prevent polypharmacy and drug misuse have not been well studied. There is a need for intensive research to define effective methods to strengthen prescribing practice of physicians for elderly patients, to promote cooperation among health care personnel in ensuring optimal drug use by patients, and to enhance the role of patients as responsible partners in drug therapy. The authors are confident, however, that drug misuse and polypharmacy can be reduced in older persons by the use of current knowledge of risk factors associated with polypharmacy and by improved communication between the physician and patient.

Entities:  

Mesh:

Year:  1992        PMID: 1576572

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  27 in total

1.  Polypharmacy in general practice: differences between practitioners.

Authors:  L Bjerrum; J Søgaard; J Hallas; J Kragstrup
Journal:  Br J Gen Pract       Date:  1999-03       Impact factor: 5.386

2.  Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study.

Authors:  S Ruths; J Straand; H A Nygaard
Journal:  Qual Saf Health Care       Date:  2003-06

3.  Therapy related hospital admission in patients on polypharmacy in Singapore: a pilot study.

Authors:  Yvonne Koh; Bte Moideen Kutti Fatimah; Shu Chuen Li
Journal:  Pharm World Sci       Date:  2003-08

4.  Characteristics of polymedicated (≥ 4) elderly: a survey in a community-dwelling population aged 60 years and over.

Authors:  N Husson; G Watfa; M-C Laurain; C Perret-Guillaume; J-Y Niemier; P Miget; A Benetos
Journal:  J Nutr Health Aging       Date:  2014-01       Impact factor: 4.075

5.  Going beyond the numbers - a call to redefine polypharmacy.

Authors:  Carmel M Hughes; Janine A Cooper; Cristin Ryan
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

6.  Reducing medication regimen complexity: a controlled trial.

Authors:  A J Muir; L L Sanders; W E Wilkinson; K Schmader
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

7.  Drug burden index score and functional decline in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

Review 8.  Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist.

Authors:  Victoria Rollason; Nicole Vogt
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy.

Authors:  Grace Lu-Yao; Ginah Nightingale; Nikita Nikita; Scott Keith; Krupa Gandhi; Kristine Swartz; Ralph Zinner; Swapnil Sharma; W M Kevin Kelly; Andrew Chapman
Journal:  J Geriatr Oncol       Date:  2020-03-19       Impact factor: 3.599

Review 10.  Optimization of drug prescribing.

Authors:  S H D Jackson; A A Mangoni; G M Batty
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.